Summary by Futu AI
Cingulate Inc., a biopharmaceutical company, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on September 26, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the potential sale of up to 1,500,000 shares of common stock by Lincoln Park Capital Fund, LLC (Lincoln Park), a selling stockholder. The shares may be sold from time to time at market prices or negotiated transactions, and the selling stockholder may use brokers or agents for the sale. The registration allows Cingulate Inc. to raise capital by selling shares to Lincoln Park over a 36-month period, subject to certain conditions, including the effectiveness of the registration statement. The proceeds from the sale of shares are intended for continued research and development, commercialization activities, working capital, and other corporate purposes. The filing also includes indemnification agreements for directors and officers, and details on the use of proceeds, legal matters, and financial statements.
